Skip to main
BBOT

BBOT Stock Forecast & Price Target

BBOT Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BridgeBio Oncology Therapeutics Inc. is positioned favorably due to its promising pipeline, which includes three wholly-owned assets currently in Phase 1 clinical trials, demonstrating significant early efficacy and safety, particularly for BBO-8520. The potential combination therapies, such as BBO-8520 with BBO-10203, present innovative approaches to overcoming resistance in treatments aimed at RAS and PI3K mutations, highlighting a substantial unmet need in the oncology landscape. Furthermore, the company's strategic leadership and experience in building partnerships for commercial growth suggest a robust operational foundation capable of driving future success in the highly competitive biopharmaceutical market.

Bears say

BridgeBio Oncology Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock. Key risks include the potential for disappointing clinical results from its lead product candidates BBO-8520, BBO-10203, and BBO-11818, which could result in lowered market penetration estimates and delayed approval timelines. Additionally, competitive threats from superior products and uncertainties around regulatory and reimbursement processes exacerbate the company's financial outlook, particularly in a landscape where the efficacy of treatments for certain cancer types remains uncertain.

BBOT has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BridgeBio Oncology Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BridgeBio Oncology Therapeutics Inc (BBOT) Forecast

Analysts have given BBOT a Buy based on their latest research and market trends.

According to 7 analysts, BBOT has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BridgeBio Oncology Therapeutics Inc (BBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.